Adjuvant Hypofractionation Radiotherapy for Thymic Epithelial Tumours After Complete Resection

Launched by CANCER INSTITUTE AND HOSPITAL, CHINESE ACADEMY OF MEDICAL SCIENCES · Dec 18, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a type of treatment called adjuvant hypofractionation radiotherapy for patients with thymic epithelial tumors after they have had surgery to remove the tumor completely. The goal is to see how effective this treatment is and what side effects it may cause. The trial is currently looking for participants aged 65 to 74 and 27 to 93, regardless of gender, who have been diagnosed with specific types of thymic tumors and have had successful surgery.

To be eligible for this trial, participants must have a confirmed diagnosis of thymoma or thymic carcinoma and must have undergone a complete resection (surgery to remove all visible tumor). They should also be in good overall health, with specific measures of lung, kidney, and liver function. However, individuals who have had previous radiation therapy to the chest, have uncontrolled health issues, are pregnant or nursing, or have pneumonia will not be able to participate. Those who join the trial can expect to receive the new treatment and undergo regular check-ups to monitor their health and any potential side effects.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Thymoma and Thymic carcinoma confirmed by histology or cytology
• • R0 resection (complete resection)
• • stage II and III thymic carcinoma，stage III thymoma，stage IIB B2/B3 thymomas.
• • Karnofsky performance status(KPS) 80, 90 or 100.
• • Having sufficient Pulmonary function, renal function and liver function. Neutrophile granulocyte count\>1.5×109 /L, platelet count\>80×109 /L, hemoglobin ≥10g/dL.
• Exclusion Criteria:
• • Prior thoracic radiotherapy.
• • Uncontrolled Comorbidities.
• • Pregnant or nursing mother.
• • Pneumonia